Cancer immunotherapy
Alemany’s & Piulats’s lab

DESCRIPTION

Our main aim is to develop new anticancer treatments based on novel designs of oncolytic adenoviruses, combining them with mesenchymal stem cells and cellular therapies derived from tumor reactive T-lymphocytes against solid tumors.

The Cancer Immunotherapy group, led by Dr Piulats and Dr Alemany, is dedicated to develop new immunotherapies based on oncolytic adenoviruses or advanced therapy medicinal products (ATMPs) to treat the so-called “cold” tumors and rare malignancies. Oncolytic viruses represent a double antitumor strategy: they have an oncolytic activity and on top of that, they promote lymphocyte infiltration and immune responses against tumors. We are designing and evaluating new oncolytic adenovirus to improve their Intratumor diffusion and tumor reactivity and testing those using murine models. We are developing CAR-NK cells models, cell therapies based on autoreactive TCRs from patients and combined ATMP using virus and mesenchymal stem cells. We combine clinical and translational research, and we have led different clinical trials based on immunotherapy, demonstrating the feasibility of immunotherapy approaches to treat this kind of tumors.

Group members

Ramón Alemany Bonastre

Group leaders

Josep Maria Piulats Rodríguez

Group leaders

Publications

Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial

3 de December de 2025/in Alemany’s & Piulats’s lab/by

ESMO Open. 2025 Dec 2;10(12):105892. doi: 10.1016/j.esmoop.2025.105892. Online ahead of print. ABSTRACT BACKGROUND: The use of immune checkpoint inhibitors (ICIs) in metastatic colorectal cancer (mCRC) remains limited to tumors harboring microsatellite instability (MSI); however, a subset of microsatellite stable (MSS) tumors features an MSI-like phenotype that could predict responses to ICIs combined with anti-angiogenesis agents. […]

Comment on: “Tebentafusp Versus Nivolumab Plus Ipilimumab for Metastatic Uveal Melanoma: An E‑Value Sensitivity Analysis Assessing Effect of Unmeasured Confounders on Observational Associations”

28 de October de 2025/in Alemany’s & Piulats’s lab/by

Clin Drug Investig. 2025 Oct 28. doi: 10.1007/s40261-025-01468-1. Online ahead of print. NO ABSTRACT PMID:41148519 | DOI:10.1007/s40261-025-01468-1

Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 patients

12 de September de 2025/in Alemany’s & Piulats’s lab/by

Clin Cancer Res. 2025 Sep 12. doi: 10.1158/1078-0432.CCR-25-1513. Online ahead of print. ABSTRACT PURPOSE: We conducted an integrated safety analysis from three clinical studies of tebentafusp, a first-in-class ImmTAC bispecific T cell engager, that can redirect T cells to target glycoprotein 100-positive cells, in metastatic uveal melanoma (mUM). EXPERIMENTAL DESIGN: HLA-A*02:01-positive patients with unresectable or […]

Toxicity and Biodistribution of the Oncolytic Virus VCN-01 Following Intracranial Injection in Syrian Hamsters

29 de August de 2025/in Alemany’s & Piulats’s lab/by

Hum Gene Ther. 2025 Aug 29. doi: 10.1177/10430342251372091. Online ahead of print. ABSTRACT Among solid pediatric tumors, brain tumors are the leading cause of cancer-related mortality. While survival rates have improved for certain pediatric brain tumor subtypes, the overall prognosis remains poor. Consequently, there is an urgent need for novel therapies that are not only […]

Final overall survival and safety analyses of the phase 3 PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer

18 de July de 2025/in Alemany’s & Piulats’s lab/by

Ann Oncol. 2025 Jul 16:S0923-7534(25)00852-X. doi: 10.1016/j.annonc.2025.07.003. Online ahead of print. ABSTRACT BACKGROUND: In PSMAfore, [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) prolonged radiographic progression-free survival (rPFS) in taxane-naive patients with metastatic castration-resistant prostate cancer (mCRPC), with a favourable safety profile, versus a change in androgen receptor pathway inhibitor (ARPI). We report the final overall survival (OS) analysis and updated […]

Research Projects

Name: Dr Ramón Alemany Bonastre
Role: Group leader (coPI)

Name: Dr Josep Maria Piulats Rodríguez, MD
Role: Group leader (coPI)

Name: Dr Rafael Moreno Olié
Role: Principal Investigator

Name: Dr María Dolores López Robles
Role: Postdoctoral researcher

Name: Dr Marcel Costa García
Role: Postdoctoral Researcher

Name: Dr Gabriel Espinosa Carrasco
Role: Postdoctoral researcher

Name: Sílvia Torres Manjón
Role: Lab manager

Name: Laura Moya Borrrego
Role: Predoctoral Researcher

Name: Pau Fiol Mata
Role: Predoctoral Researcher

Name: Luís Paul del Carpio Huerta, MD
Role: Predoctoral Researcher (Rio Ortega contract)

Name: Juan Antonio Marín Jiménez, MD
Role: Predoctoral Researcher (La Caixa- Inphinit Retaining)

Name: Sebastián Ciro Carné Martín
Role: Predoctoral Researcher

Name: Ainhoa Muñoz Metrino
Role: Technician

Name: Dr Carles Codony Servat
Role: Project manager

Collaborations

Dr Alemany has published 129 articles, several book chapters and 16 patents (5 in the exploitation phase) in the field of therapeutic use of adenoviruses as gene vectors or oncolytic viruses. Editor of the journals “Gene Therapy” “Cancer Gene Therapy” and “Human Gene Therapy”, President of the Spanish Society of Gene and Cellular Therapy from 2016 to 2018, and advisor to several biotech companies that develop oncolytic viruses (ORCA Therapeutics, Oncolytics Biotech, Sagetis). In 2009 he co-founded the company VCN Biosciences. GHe collaborates among othersc with: Cristina Fillat Fonts, IDIBAPS; Juan José Rojas Expósito, IDIBELL; Javier García Castro, ISCIII , Madrid; Manuel Ramírez Orellana, Hosp Niño Jesús, Madrid; Alena Gros Vidal, VHIO; Sonia Guedan Carrió, IDIBAPS.

Dr Piulats is chair for Uveal Melanoma in the Spanish Melanoma group. He is part of the IRCI (International Rare Cancer Initiative) and EURACAN for rare melanoma and rare cutaneous tumors. He collaborates with Dr Alvaro Aytes (Idibell) and Dr Himisha Beltran (Dana Farber) in prostate cancer (projects Fundación Mútua Madrileña and DoD Prostate Cancer) and with Dr Xavier Matías-Guiu and Dr Alena Gros in Gynecologic tumors (La MaratóTV3, Immune4all in Ayudas de Proyectos de Investigación de Medicina Personalizada de Precisión). He collaborates with Dr Moreno (ICO-Idibell) and Dr África González Murillo (Hospital Universitario del Niño Jesús) in the PULSE-UM clinical study and with Dr Juan Marín Liberal (ICO), Drs Alena Gros, Elena Garralda (VHIO), Dr Sergi Querol (Banc de sang i Teixits) and Dr Jesús García-Donas Jiménez (Centro Integral Oncológico Clara Campal) (Proyectos Clinica Independiente – ISCIII).

Presently Dr Piulats has begun a collaboration asking for new funding for novel treatments in metastatic uveal melanoma with Alena Gros (VHIO), Gal Cafri and Yochai Wolf from Sheba Research Institute in Israel and Udai Kammula from UPMC in USA.

Dr Moreno collaborates in the development of NK-CAR cells with Dr Ana Sureda (ICO). He also collaborates with Dr. Marta Alonso (CIMA-University of Navarra) in the development towards a protocol and clinical application for GBM.

Cancer immunotherapy Alemany’s & Piulats’s lab

DESCRIPTION

Ramón Alemany Bonastre

Group leaders

Josep Maria Piulats Rodríguez

Group leaders

Rafael Moreno Olié

Researchers

María Dolores López Robles

Researchers

Gabriel Espinosa Carrasco

Researchers

Marcel Costa García

Researchers

Luís Paul del Carpio Huerta

Researchers

Juan Antonio Marín Jiménez

Young investigators

Laura Moya Borrego

Young investigators

Pau Fiol Mata

Young investigators

Sebastián Ciro Carné Martín

Young investigators

Silvia Torres Manjón

Support staff

Ainhoa Muñoz Metrino

Support staff

Carles Codony Servat

Support staff

CONTACT US

Cancer immunotherapy
Alemany’s & Piulats’s lab